Home › New Analysis from Investigational IMPROVE-IT Study Shows VYTORIN (ezetimibe/simvastatin) Reduced Total (Initial and Recurrent) Cardiovascular Events More than Simvastatin Alone in Patients Presenting with Acute Coronary Syndromes
 

Keywords :   


New Analysis from Investigational IMPROVE-IT Study Shows VYTORIN (ezetimibe/simvastatin) Reduced Total (Initial and Recurrent) Cardiovascular Events More than Simvastatin Alone in Patients Presenting with Acute Coronary Syndromes

2015-03-16 20:30:00| Merck.com - Product News

Dateline City: SAN DIEGO SAN DIEGO--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced results from a pre-specified exploratory analysis of the investigational IMPROVE-IT study of more than 18,000 patients presenting with acute coronary syndromes. Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558orMichael Close, 267-305-1211orInvestors:Justin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: with total events study

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
07.11Remnants of Fourteen-E Graphics
07.11Remnants of Fourteen-E Forecast Discussion Number 6
07.11Remnants of Fourteen-E Wind Speed Probabilities Number 6
07.11Remnants of Fourteen-E Public Advisory Number 6
07.11Summary for Remnants of Fourteen-E (EP4/EP142024)
07.11Remnants of Fourteen-E Forecast Advisory Number 6
07.11Hurricane Rafael Graphics
07.11Hurricane Rafael Forecast Advisory Number 17
More »